.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EJ03_Pacritinib.Pacritinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EJ03_Pacritinib.Pacritinib| name: | Pacritinib | |
| ATC code: | L01EJ03 | route: | oral |
| compartments: | 2 | |
| dosage: | 200 | mg |
| volume of distribution: | 267 | L |
| clearance: | 19.8 | L/h |
| other parameters in model implementation | ||
Pacritinib is an oral, selective inhibitor of Janus-associated kinases JAK2 and FLT3 used for the treatment of myelofibrosis, particularly in patients with thrombocytopenia. It is approved for use in several countries for adults with intermediate- or high-risk primary or secondary myelofibrosis.
Population pharmacokinetic parameters reported in adult patients with myelofibrosis, following oral administration as part of clinical development.